<DOC>
	<DOCNO>NCT01784536</DOCNO>
	<brief_summary>The purpose study examine effect oritavancin vivo activity CYP1A2 , CYP2C9 , CYP2C19 , CYP2D6 , CYP3A , NAT 2 , XO use Cooperstown 5 + 1 cocktail open label , single arm manner .</brief_summary>
	<brief_title>Open Label Study Evaluating Effects Single Oritavancin Infusion Cytochrome P450 Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Oritavancin</mesh_term>
	<criteria>Provides write informed consent study initiation . Healthy male female adult 18 45 year age , inclusive . Body mass index ( BMI ) 18 32 kg/m2 , inclusive . Nonsmoker 6 month period Screening . In good health base upon result medical history , physical examination , clinically significant 12lead ECG result , laboratory test result . Agrees avoid medication ( study drug ) may inhibit induce hepatic microsomal enzyme study period , include prescription nonprescription medication , vitamin , herbal supplement ( include energy drink ) , nutraceuticals . Female subject surgically sterile , postmenopausal , , childbearing potential , agree use acceptable nonhormonal method contraception study phase . Agree abstain alcohol , caffeine , xanthinecontaining product , kind energy drink consumption grapefruit juice orange juice 48 hour study drug administration completion followup visit . Has acute chronic respiratory disease . The use nonprescription drug 30 day period screen . The use prescription drug 3 month period . Childbearing potential , positive test result urine serum , human chorionic gonadotropin ( hCG ) Screening . Positive serology result hepatitis B surface antigen , hepatitis C virus antibody , know hepatitis B C infection screen . Positive serology result human immunodeficiency virus ( HIV ) know immune deficiency disease Screening . Requires anticoagulant monitoring activate partial thromboplastin time . Has elevate international normalized ratio &gt; 1.3 . Surgical medical condition could interfere administration study drug . Any condition may affect drug absorption . Has know intolerance benzodiazepine , active and/or inactive ingredient caffeine , warfarin , vitamin K , omeprazole , dextromethorphan . The use nicotine contain substance nicotine replacement device within 6 month Screening . Has receive immunization 2 week period screening . Has hemorrhagic tendency blood dyscrasia . Has poor venous access determine investigator . Reports regular alcohol intake exceed 1 drink/day within 1 month screening . A poor metabolizer ( base medical history , know ) CYP2D6 , CYP2C9 , CYP2C19 . Has participate clinical research study involve evaluation investigational drug device within 30 day enrollment . Excluded previous criterion may rescreened participation time .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>April 2013</verification_date>
</DOC>